Over recent years, preclinical and clinical evidence has implicated myocardial inflammation
(M-Infl) in the pathophysiology and phenotypes of traditionally genetic cardiomyopathies. M …

Hypertrophic cardiomyopathy (HCM) is a global and relatively common cause of patient
morbidity and mortality and is among the first reported monogenic cardiac diseases. For 30 …

Introduction: The development of patient-specific induced pluripotent stem cell-derived
cardiomyocytes (iPSC-CMs) offers an opportunity to study genotype-phenotype correlation …

Noonan syndrome (NS), the most common among RASopathies, is caused by germline
variants in genes encoding components of the RAS-MAPK pathway. Distinct variants …

Gene therapy is advancing at an unprecedented pace, and the recent success of clinical
trials reinforces optimism and trust among the scientific community. Recently, the cardiac …

Introduction Diabetic ketoacidosis (DKA) is a severe and potentially fatal acute complication
in diabetic patients, commonly occurring in type 1 diabetes (T1D) but also seen in type 2 …

Determining the pathogenicity of hypertrophic cardiomyopathy–associated mutations in the
β-myosin heavy chain (MYH7) can be challenging due to its variable penetrance and clinical …

Hypertrophic cardiomyopathy (HCM) is a genetic heterogeneous disorder and the main
cause of sudden cardiac death in adolescents and young adults. This study was aimed at …

Patients with hypertrophic cardiomyopathy (HCM) mostly experience minimal symptoms
throughout their lifetime, and some individuals have an increased risk of ventricular …

Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic
cardiomyopathy. Pathogenic germline variation in genes encoding the sarcomere is the …